Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Incyte’s Jakafi Gets Broad Label, Early Approval For Myelofibrosis

This article was originally published in The Pink Sheet Daily

Executive Summary

Incyte Corp. hits the trifecta – a first-in-class, first-in-disease and first launch with the Nov. 16 FDA approval of Jakafi (ruxolitinib) for treatment of the progressive bone marrow cancer.

You may also be interested in...



Ahead Of Ryoncil’s Advisory Committee, Citizen Petition Opposes Approval For Pediatric GVHD

Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.

Keeping Track: Accelerated Approval For Tecentriq And A Burst Of Filings And Submissions

The latest drug development news and highlights from our US FDA Performance Tracker. 

CTI Lands Baxter As Pacritinib Partner To Try To Reach Finish Line

The beleaguered oncology company has inked a partnership for its third late-stage candidate with hopes of taking it through approval, unlike its last two attempts.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073059

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel